Triple
T19157619
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | maftivimab |
E468964
|
entity |
| Predicate | actsSynergisticallyWith |
P134654
|
FINISHED |
| Object | atoltivimab |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: atoltivimab | Statement: [maftivimab, actsSynergisticallyWith, atoltivimab]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: atoltivimab Context triple: [maftivimab, actsSynergisticallyWith, atoltivimab]
-
A.
ansuvimab
Ansuvimab is a monoclonal antibody used as a therapeutic treatment for infection caused by Zaire ebolavirus (Ebola virus).
-
B.
odesivimab
chosen
Odesivimab is a monoclonal antibody used as part of an antibody cocktail therapy for the treatment of Ebola virus infection.
-
C.
maftivimab
Maftivimab is a monoclonal antibody used as part of an antibody cocktail therapy for the treatment of Ebola virus infection.
-
D.
Ofatumumab
Ofatumumab is a fully human monoclonal antibody used primarily in the treatment of certain B‑cell malignancies and relapsing forms of multiple sclerosis.
-
E.
idarucizumab
Idarucizumab is a monoclonal antibody fragment used as a specific antidote to rapidly reverse the anticoagulant effects of dabigatran in cases of emergency or uncontrolled bleeding.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: actsSynergisticallyWith Context triple: [maftivimab, actsSynergisticallyWith, atoltivimab]
-
A.
administeredAlongside
Indicates that one treatment, drug, or intervention is given or applied at the same time as another.
-
B.
assistsWith
Indicates that one entity helps or supports another entity in performing or accomplishing a specific task, activity, or objective.
-
C.
implementedInCooperationWith
Indicates that an action, project, or initiative was carried out jointly or collaboratively together with another party.
-
D.
definesCooperationWith
Indicates that one entity formally specifies or establishes the terms, scope, or nature of cooperative interaction with another entity.
-
E.
alsoComposedWith
Indicates that something is created or formed together with one or more additional components, highlighting a joint or complementary composition relationship.
- F. None of above. chosen
Provenance (4 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d8dd084ff48190ac0f8c46ee722629 |
completed | April 10, 2026, 11:20 a.m. |
| NER | Named-entity recognition | batch_69e5eeba91a081909c04d61d6117da06 |
completed | April 20, 2026, 9:15 a.m. |
| PD | Predicate disambiguation | batch_69e4b9b83d6881908e6271c620f74100 |
completed | April 19, 2026, 11:17 a.m. |
| PDg | Predicate description generation | batch_69e4bfe9ef7081908a74a57d1fc731ea |
completed | April 19, 2026, 11:43 a.m. |
Created at: April 10, 2026, 12:06 p.m.